Evidence map›Paper›PMID 33771971›Full record

ArticleBlood cancer journal2021

Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure.

Jennifer J Gile, Camden L Lopez, Gordon J Ruan, Matthew A Hathcock, Jithma P Abeykoon, Joy R Heimgartner, Nikola A Baumann, M Molly McMahon, Ivana N Micallef, Patrick B Johnston and 6 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06987708 (Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers Associated With Monoclonal Gammopathy of Unknown Significance), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06987708 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers Associated With Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Myeloma (SM): A Prospective Intervention Pilot Study

TypeinterventionalSponsorHackensack Meridian HealthRan2026 to 2028Enrolled67ConditionsMonoclonal Gammopathy of Uncertain Significance, Smoldering MyelomaArmsThe Multimodal Lifestyle Intervention
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Jennifer J Gile *Division of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.ORCID 0000-0001-6972-7986
Camden L Lopez *Department of Biomedical Statistics and Informatics, Mayo Clinic Rochester, Rochester, MN, 55905, USA.ORCID 0000-0003-4516-8088
Gordon J RuanDivision of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.
Matthew A HathcockDepartment of Biomedical Statistics and Informatics, Mayo Clinic Rochester, Rochester, MN, 55905, USA.
Jithma P AbeykoonDivision of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.
Joy R HeimgartnerDivision of Endocrinology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.
Nikola A BaumannDepartment of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, 55905, USA.
M Molly McMahonDivision of Endocrinology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.
Ivana N MicallefDivision of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.
Patrick B JohnstonDivision of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.
Jose C Villasboas BisnetoDivision of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.
Luis F PorrataDivision of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.
Jonas PaludoDivision of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.ORCID 0000-0002-7350-5531
Stephen M AnsellDivision of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.
William J HoganDivision of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA.ORCID 0000-0002-5841-4105
Thomas E WitzigDivision of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN, 55905, USA. Witzig.Thomas@Mayo.Edu.ORCID 0000-0002-4215-6500
Mayo Clinic · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7M
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA097274
6 · The paper itself

Abstract

Magnesium is an essential element that is involved in critical metabolic pathways. A diet deficient in magnesium is associated with an increased risk of developing cancer. Few studies have reported whether a serum magnesium level below the reference range (RR) is associated with prognosis in patients with diffuse large B cell lymphoma (DLBCL). Using a retrospective approach in DLBCL patients undergoing autologous stem cell transplant (AHSCT), we evaluated the association of hypomagnesemia with survival. Totally, 581 patients eligible for AHSCT with a serum magnesium level during the immediate pre-transplant period were identified and 14.1% (82/581) had hypomagnesemia. Hypomagnesemia was associated with an inferior event-free (EFS) and overall survival (OS) compared to patients with a serum magnesium level within RR; median EFS: 3.9 years (95% CI: 1.63-8.98 years) versus 6.29 years (95% CI: 4.73-8.95 years) with HR 1.63 (95% CI: 1.09-2.43, p = 0.017) for EFS, and median OS: 7.3 years (95% CI: 2.91-upper limit not estimable) versus 9.7 years (95% CI: 6.92-12.3 years) with HR 1.90 (95% CI: 1.22-2.96, p = 0.005) for OS months 0-12, respectively. These findings suggest a potentially actionable prognostic factor for patients with DLBCL undergoing AHSCT.

Indexed as

Hematopoietic Stem Cell TransplantationAdultAgedFemaleHumansLymphoma, Large B-Cell, DiffuseMagnesiumMagnesium DeficiencyMaleMiddle AgedPrognosisRetrospective StudiesSurvival AnalysisTransplantation, AutologousYoung AdultMagnesium

Identifiers

PMID33771971
PMCPMC7998023
OpenAlexW3139144223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.